Nearly three‐quarters of participants were treated with an ACE inhibitor or ARB at doses 50% or more of the maximal daily antihypertensive dose, ensuring that placebo‐treated patients were receiving guideline‐concordant care for CKD with albuminuria. Here, ACE is linked to chronic kidney disease.